XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of anti-dilutive net (loss) income per share

		For the Three Months Ended September 30,
		(Unaudited)
		2024				2023
Warrants			2,734,596				-
Convertible Debt			2,080,000
Options			573,000				-
			5,387,596				-

Schedule of Product and service revenue under disaggregation of revenue

		For the Three Months Ended September 30,
		(Unaudited)
		2024				2023
Net Income (Loss)		$	58,962			$	(900,780	)
Adjustments for convertible debt - as converted
Net income (loss) attributable to common shareholders		$	58,962			$	(900,780	)
Weighted average number of shares of common stock outstanding:
Basic			20,015,205				19,823,955
Net income (loss) attributable to common shareholders per share:
Basic		$	0.00			$	(0.05	)

		For the Nine Months Ended September 30,
		(Unaudited)
		2024				2023
Net Income (Loss)		($1,221,030)				($2,176,858)
Net income (loss) attributable to common shareholders		($1,221,030)				($2,176,858)
Weighted average number of shares of common stock outstanding:
Basic			19,984,179				19,818,241
Net income (loss) attributable to common shareholders per share:
Basic and Diluted		($0.06)				($0.11)

Schedule of Revenue by Geographic Region under disaggregation of revenue

		For the Three Months Ended September 30,
		(Unaudited)
		2024				2023
Numerator:
Net Income (Loss)		$	58,962			$	(900,780	)
Denominator:
Basic weighted-average shares			20,015,205				19,823,955
Effect of dilutive securities
Warrants			5,908				-
Options			11,888				-
Preferred Stock			63,750				-
Diluted Weighted Average Shares			20,096,751				19,823,955
Net income (loss) attributable to common shareholders per share:
Diluted		$	0.00			$	(0.05	)

		For the three months ended September 30, (Unaudited)
		2024				2023
SteraMist Product		$	1,766,000			$	953,000
Service and Training			776,000				517,000
Total		$	2,542,000			$	1,470,000

		For the three months ended September 30, (Unaudited)
		2024				2023
United States		$	1,886,000			$	1,271,000
International			656,000				199,000
Total		$	2,542,000			$	1,470,000

		For the nine months ended September 30, (Unaudited)
		2024				2023
SteraMist Product		$	5,247,000			$	4,501,000
Service and Training			1,423,000				1,326,000
Total		$	6,670,000			$	5,827,000

		For the nine months ended September 30, (Unaudited)
		2024				2023
United States		$	5,169,000			$	5,001,000
International			1,501,000				826,000
Total		$	6,670,000			$	5,827,000

X

- References

No definition available.

+ Details

Name:	tomz_ScheduleOfAntiDilutiveNetLossIncomePerShareTableTextBlock
Namespace Prefix:	tomz_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	tomz_ScheduleOfRevenueByGeographicRegionUnderDisaggregationOfRevenueTableTextBlock
Namespace Prefix:	tomz_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration